At a glance
Summary
Quest Diagnostics ended the week at 209.9 USD after a 7.6% advance, leaving the stock at 94.6% of its 52-week range and 9.5% above its weekly Trend Line. The Trend backdrop remains active with a 24-week streak and 49 active weeks out of the past 52, while activity pressure turned positive at 0.08 after several weaker readings. The evidence is constructive, but not clean: volume was 5.0M shares, only 1.1x the 13-week average, and the Fair Value gap has widened to 34.1%.
- DGX rose 7.6% in the latest completed week, closing at 209.9 USD, just 1.3% below its 212.6 USD 52-week high.
- The weekly Trend Signal remains active, with price 9.5% above the 191.7 USD Trend Line and trend breadth active in 49 of 52 weeks.
- Volume improved to 5.0M shares, but at 1.1x the 13-week average it offers only moderate confirmation.
- Activity pressure turned positive at 0.08 and relative strength improved to 4.42, while the signal set still shows no fresh buy from activity pressure.
- Healthcare breadth is mixed: DGX beat the sector’s 5.2% weekly return and slightly outpaced the Diagnostics & Research industry’s 7.4%, but industry relative-strength breadth remains low at 33.3%.
Company analysis
The move in context
High-range close comes with a revived pressure read
Quest Diagnostics delivered one of its stronger weekly moves of 2026, rising 7.6% to 209.9 USD. The close leaves the clinical-lab operator near the top of its annual range, only 1.3% below the 52-week high of 212.6 USD and well above the 52-week low of 162.5 USD. The weekly Trend backdrop remains active, with a 24-week active streak and 94.2% trend breadth across the past year.
The move repaired some of the short-term softness visible earlier in June. Activity pressure improved to 0.08 from negative readings in the prior four weeks, while relative strength rose to 4.42. That is enough to keep the weekly read constructive, but the signal state is not fully confirmed: activity pressure is positive, yet there is no fresh buy signal, and the stock now trades 34.1% above Sharemaestro Fair Value at 156.5 USD.
Healthcare context is supportive, but industry breadth is uneven
DGX outpaced the US Healthcare group’s 5.2% average weekly return and ranked in the upper third of the sector for the week. It also slightly exceeded the US Diagnostics & Research industry’s 7.4% weekly return, although its 12-week gain of 6.4% trails the industry’s 15.7% average, showing that the latest push is doing more of the work than the quarterly trend.
Breadth argues for selectivity rather than a broad all-clear. In Healthcare, only 37.0% of names show active weekly trend signals, with positive Market Dynamics at 52.0% and positive Relative Strength at 44.0%. In Diagnostics & Research, the contrast is sharper: Market Dynamics breadth is strong at 77.1%, but trend breadth is only 31.2% and Relative Strength breadth is 33.3%. DGX sits on the stronger side of that split, with active trend, positive Market Dynamics and positive Relative Strength.
Volume supports the move, but not emphatically
Participation improved to 5.0M shares in the latest week, above the 13-week average of 4.4M and the 52-week average of 4.7M. The 1.1x volume ratio is a useful confirmation step after the prior week’s 4.0% decline on 4.1M shares, but it falls short of the stronger participation typically associated with a decisive high-range breakout.
Risk remains balanced rather than stretched by volatility. Thirteen-week weekly-return volatility is 3.1%, close to the 52-week baseline of 3.2%. The one-year split shows 30 positive weeks and 22 negative weeks, with average up weeks and down weeks both around 2.5% in magnitude. The main near-term risk is less about volatility and more about exhaustion near the high, especially with two recent reversal markers in the smart-money tape and only moderate volume behind the rebound.
What to watch next
The immediate test is whether DGX can hold its position above the 191.7 USD Trend Line while challenging the 212.6 USD high. A continued positive activity-pressure reading would strengthen the case that the latest move is more than a one-week rebound, while any fade back into negative pressure would weaken the quality of the advance.
Volume is the cleaner confirmation gauge from here. A ratio closer to or above 1.5x would show broader participation in the next leg, while another push toward the high on merely average turnover would keep the breakout evidence incomplete. The Fair Value premium also deserves attention: at 34.1%, the stock already reflects substantial demand relative to the model, leaving less room for disappointment if momentum cools.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line37.0%
Positive Relative Strength44.0%
US Diagnostics & Research
48 tracked companiesAbove Trend Line31.3%
Positive Relative Strength33.3%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 24-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- The Expectancy Model is positive at 55.65%, strengthening the forward tape read.
What needs caution
- Activity pressure is weak, so confirmation is not yet broad enough.
- 2 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/quest-diagnostics-high-range-pressure-volume/.
Follow new Sharemaestro research through the RSS feed or JSON feed.